Key result
Tonlamarsen reduces circulating angiotensinogen by up to ~79% and lowers SBP versus placebo.
Why the study?
Does subcutaneous tonlamarsen reduce circulating angiotensinogen and systolic blood pressure in healthy participants and patients with uncontrolled hypertension?
RCT
Does subcutaneous tonlamarsen reduce circulating angiotensinogen and systolic blood pressure in healthy participants and patients with uncontrolled hypertension?
Tonlamarsen safely achieves substantial reductions in circulating angiotensinogen and lowers systolic blood pressure, supporting hepatic AGT suppression as a novel therapeutic strategy for uncontrolled hypertension.
Answers are grounded in this paper and cite their sources.
Tonlamarsen supports advancing hepatic AGT suppression for hypertension; leaves open confirmation of sustained BP effects and outcomes in larger trials.
Tonlamarsen, a hepatocyte-directed antisense oligonucleotide targeting angiotensinogen (AGT), produced rapid, dose-dependent reductions in circulating AGT in healthy participants and patients with uncontrolled hypertension. A single dose reduced AGT by up to 75.2%, while monthly dosing achieved reductions of up to 79.0% after 4 doses. Tonlamarsen was generally well tolerated, with no clinically meaningful effects on platelet count, potassium, renal function, liver enzymes, or hypotension. Exploratory analyses demonstrated lower systolic blood pressure with tonlamarsen than placebo. These findings support further evaluation of hepatic AGT suppression as a novel therapeutic strategy for hypertension. A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension: NCT05314439).
No takes yet. Share an insight, caveat, or question.
Morgan et al. (2026) conducted an RCT in Uncontrolled hypertension. Tonlamarsen (ION904) vs. Placebo was evaluated on Reduction in circulating angiotensinogen (AGT). Tonlamarsen reduced circulating angiotensinogen by up to 75.2% after a single dose and 79.0% after 4 monthly doses while lowering systolic blood pressure compared with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: